OncoMatch/Clinical Trials/NCT06560905

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Is NCT06560905 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 68Ga-PSMA for malignant melanoma.

Phase 2RecruitingRoyal Marsden NHS Foundation TrustNCT06560905Data as of May 2026

Treatment: 68Ga-PSMA — This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Disease stage

Metastatic disease required

Prior therapy

Cannot have received: lu-177 psma therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify